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Background: Patient non-adherence to medicines represents a significant waste of health resource and lost
opportunity for health gain. Medicine management services are a key health policy strategy to encourage patients
to take medicines as they are prescribed. One such service is the English Medicines Use Review (MUR) which is an
NHS-funded community pharmacy service involving a patient-pharmacist consultation aiming to improve patients’
knowledge of medicines and their use. To date the evidence for MURs to improve patient health outcomes is
equivocal and GPs are reported to be sceptical about the value of the service. This paper presents the patient’s
perspective of the MUR service and focuses on the importance of GP-pharmacist collaboration for patient care.
Suggestions on how MURs may have value to GPs through the delivery of increased patient benefit are discussed.
Method: A qualitative study involving ten weeks of ethnographic observations in two English community
pharmacies. Observations were made of all pharmacy activities including patient-pharmacist MUR consultations.
Subsequent interviews with these patients were conducted to explore their experience of the service. Interviews
with the pharmacy staff were conducted after the period of observations. A thematic approach was used to analyse
the data.
Results: Fifty-four patients agreed to have their MUR observed of which thirty-four were interviewed. Seventeen
pharmacy staff were also interviewed. Patients reported positive views about MURs. However, there was little
evidence suggesting that pharmacists and GPs were working collaboratively or communicating outcomes resulting
from MURs. MURs were conducted in isolation from other aspects of patient care. Patients considered GPs to have
authority over medicines making a few wary that MURs had the potential to cause tensions between these
professionals and possibly adversely affect their own relationship with their doctor.
Conclusions: This study reveals the potential for effective GP-pharmacist collaboration to improve the capacity of
the MUR service to support patient medicine taking. Closer collaboration between GPs and pharmacists could
potentially improve patients’ use of medicines and associated health care outcomes. The current lack of such
collaboration constitutes a missed opportunity for pharmacists and GPs to work together with patients to improve
effective prescribing and optimise patient use of medicines.
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Multiple medicines are often prescribed to manage co-
morbidities associated with an aging population resulting in
patients having to manage complex medication regimes. A
considerable body of evidence suggests that patients have
practical problems with taking medicines or may even be* Correspondence: Asam.Latif@nottingham.ac.uk
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reproduction in any medium, provided the orreluctant to take them because of concerns about side
effects, the consequences of dependency or being unclear
about the benefits [1,2]. Patient adherence to prescribed
medicines can be as low as 50 per cent and represents a lost
opportunity for improving health outcomes with conse-
quent increase in hospitalisation [3-5]. One evaluation
estimates that in England the gross annual cost of NHS pri-
mary care prescription medicines wastage is £300 million
per year including £90 million worth of unused prescription. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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million returned to community pharmacies [6]. Despite the
rising cost of treatment, prescribers may be unaware of the
level of patient medicine adherence and may not have time,
or be averse to discussing this during the medical consult-
ation [2,7,8]. There is growing acceptance that prescribing
is a partnership with patients [9]. However, some patients
may not feel the General Practitioner (GP) has time to
discuss their concerns [10,11]. There may still be continu-
ing conformity to the traditional patient role and deference
to professional authority that limits discussions about
treatment [12,13]. There is great scope for interventions
to optimise medicines use including improvements in
physician communication during prescribing and the
promotion of patient-centred care [14-16]. Alongside
these approaches are medicine management services such
as medication reviews [3,17,18]. In the UK, and internation-
ally, medication reviews are increasingly being formalised
and commissioned through community pharmacies as they
are seen to support patient medicine adherence [19-23].
These services are part of a range of extended pharmacy
services that aim to raise the professional status of
pharmacy and make better use of the pharmacist’s skills
[24]. However, pharmacists may require consultation skills
training for these newer roles to ensure patients’ complex
needs surrounding medicines are met [1,2].
This paper is concerned with the English community
pharmacy Medicines Use Review (MUR) service which
became available since 2005. An MUR involves a patient-
pharmacist consultation to discuss the patient’s use of
medicines and improve their knowledge about their
purpose [20]. Patients are eligible for the service if they have
been prescribed two or more medicines and are regular
users of the pharmacy. Pharmacists may communicate
outcomes resulting from MURs to the patient’s GP by
sending them a report of the recommendations [25]. MURs
performed with patients with asthma have suggested the
most benefit [26,27]. One study aiming to quantify the
effects of performing an MUR on GP prescribing for pa-
tients with CHD, found 56% of the pharmacists’ recom-
mendations had been actioned [28]. Nevertheless, GPs have
expressed concerns that MURs are conducted in isolation
from them, that they duplicate work and that paperwork is
overcomplicated and unavailable in an electronic format
[29,30]. Furthermore, GPs consider MURs to provide little
benefit to either their patients or themselves and make no
contribution to their contractual Quality and Outcomes
Framework (QOF) measures [29-32]. Some GPs may
consider the community pharmacist role primarily as a
‘shopkeeper’ and distant from direct patient care [33].
Despite this, over 8,000 English community pharmacies
are engaging with, and claiming payment for, the MUR
service and in 2011-2012 over 2 million MURs were
conducted at a cost of £68m [34].Researching the MUR service, its implementation and
the patient perspective is challenging. There has been
little research attempting to explore the MUR consultation
as it is naturally implemented in practice as the service is
often offered ‘on the spot’ when the patient presents to fill
their prescription. The aim of this study was to use a small
number of case study sites to develop detailed knowledge
of the pharmacy’s implementation of MURs and patient
experience rather than more superficial knowledge involving
a larger number of pharmacy sites. As such, we make no
claims about statistical representation or generalisation to a
larger population. A qualitative approach was undertaken
which was exploratory, inductive in nature and oriented to
answering ‘why’ and ‘how’ questions. By investigating MURs
in this way, we can learn about how people respond in their
natural settings and so achieve a better understanding of
their perception of MURs and how the service fits into the
system of wider health care. The aim of this study was to
investigate the patient perspective of the MUR service
and this paper examines the scope for more effective
GP-pharmacist collaboration in order to develop the MUR
as resource to improve health outcomes for patients.
Methods
Recruitment of pharmacy sites
Following approval from the East Midlands (Nottingham 2)
NHS Research Ethics Committee, two English community
pharmacies, one ‘multiple’ (part of a chain retailer) and one
‘independent’ (defined in the UK as up to five pharmacies
with the same owner) were recruited to learn about the
different contexts in which MURs were being performed.
A pragmatic approach was taken to recruit the multiple
involving contacting AL’s previous employer and seeking
permission to perform the research in one of their
branches. Permission was sought from the Company’s
Head Office and a pharmacy was selected based upon
the pharmacy conducting a reasonable number of
MURs to ensure recruitment to the study. Pharmacies
that the researcher had previously worked in regularly
were avoided to reduce the potential of being mistaken, by
pharmacy staff, for the pharmacist on duty.
The independent pharmacy was identified from a list
of all the independent pharmacies that were located in
the Nottingham and Nottingham County PCT areas.
Pharmacies were identified by a member of the University’s
pharmacy academic team who was involved with under-
graduate community pharmacy placements and through
a local locum pharmacist who had local knowledge of
which pharmacies were actively offering the MUR service.
Five invitation letters were sent during August 2008 inviting
the pharmacy to the study. However, all reported either not
regularly performing MURs on a regular basis or reported
being ‘too busy’ to participate. Another five independent
pharmacies were identified and approached. This time, only
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expressed interest in taking part in the study.
Fieldwork
Consent was obtained from the pharmacists and support-
staff for five weeks of observations in each pharmacy.
One-week placements over a 12-month period between
November 2008 and October 2009 allowed the data
collection and analysis phases to proceed simultaneously.
Ethnographically-oriented unstructured observations were
made by AL of all pharmacy activities that seemed relevant
to the situation being studied and the context in which they
occurred, including all activities relating to the MUR
service. Pharmacies were requested to display posters
within the pharmacy to promote patient awareness of the
study. All pharmacy staff were requested to identify and
invite patients for MURs as per normal practice and intro-
duce the research to those who accepted the offer of an
MUR. Eight patients were observed to decline the offer of
an MUR: one patient from the independent and seven from
the multiple. All the remaining patients who were invited
agreed to an MUR and to participate in the research; at this
point AL was introduced. MURs were carried out within a
private consultation room and AL made hand written notes
of the patient-pharmacist interaction with a fuller account
being written up afterwards. Audio or video recording the
MUR consultation would have provided verbatim data.
However it was decided, upon considering the ethical issue
of recording patient’s MUR consultation with little prior
notice, that hand written notes would be used. This would
produce a less detailed account of the MUR but it was felt
that this was less intrusive and a necessary compromise.
In order to build on the researcher’s account and to
triangulate the findings, interviews were held with both
patients and pharmacy staff. Patients were invited to take
part in a semi-structured interview about the experience to
clarify, confirm and expand on the observational data. After
the pharmacy observations were completed, pharmacy staff
took part in interviews to discuss their perceptions of the
MUR service. Details of the interview topic guides have
been reported elsewhere [35]. Permission was obtained
from participants for direct quotes to be used in reports
and publications. In this paper pseudonyms have been used
in quoted extracts to maintain respondents’ anonymity.
Data analysis was iterative and started during the early
stages of data collection. All observation field note
documents were typed up, interviews transcribed verbatim
and the data then imported into the qualitative software
programme N-Vivo8. A thematic approach to analysing the
qualitative data was used and involved initially reading and
re-reading each section of the text and collating them
under different headings or ‘codes’ [33,36]. Codes were
inductively constructed based upon what was observed and
reported in interviews and then systematically read throughand the contents condensed, synthesised and narrated.
The principle of constant comparison was used to develop
and refine generated themes [36,37] which allowed exam-
ination of how MURs were constructed, interpreted
and contextualised within the overall management of
the patient’s health care.
Results
Setting and participants
The multiple pharmacy was located in a relatively affluent
town, on a busy high street and the independent in a
similarly affluent but residential suburb. The number of
prescription items that was dispensed from each pharmacy
was approximately the same (1600–1700 per week).
Fifty-four patients consented for AL to observe their
MUR consultation of which 34 patients agreed to be
interviewed about their experience of the MUR. Pa-
tient interviews were typically conducted a week after
the observed MUR and took place at the pharmacy
(two at the University of Nottingham), lasted approximately
45 minutes and were audio-recorded. After the obser-
vations all five pharmacists (two employees from the
multiple; one owner, one employee and one regular
locum from the independent) who had been observed
during the study were interviewed plus 12 (out of 14)
pharmacy support-staff.
The MUR
Invitations to take part in MURs were typically initiated
by the pharmacy staff in an ad hoc way when patients
attended to collect prescriptions. Both pharmacies had
previously tried making appointments with patients but
these were seen to be problematic when patients did not
attend. Particularly in the independent, patients with
whom the staff appeared to have a good relationship were
typically selected for an MUR. Although GPs can refer pa-
tients, no MURs were initiated via this route. MURs were
not understood by patients to be a collaborative activity
involving or relevant to, the GP but as a quick pharmacy
oriented activity to “check” their medicines:
Primrose: The lady came up to me and said would I
mind going through my medication with the pharmacist
and just to kind of make sure that we both knew why
this medication was being prescribed and it was just
something that chemists are having to do now.
Patient 56yr. F
Among most patients involved in this study the
pharmacist did not identify many, or even any, problems
with their medicines. Most patients reported the consult-
ation had not improved upon their knowledge of their
medicines and rarely affected their use. They were generally
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their medicines, being familiar with drugs prescribed for
long-term conditions:
Jill: [Sighs] Well I don’t think I’ve got no more
knowledge. I think it’s just that I’ve been on these for so
long and once you’ve been on them for so long, the
doctor does make sure that you’re alright with them.
Patient 64yr. F
Despite a lack of evidence that the MUR service was
achieving its intended policy aims, nearly all patients
spoke of the MUR positively, describing the review as
“satisfying” or “interesting”. All patients reported feeling
comfortable speaking with the pharmacist who they saw
as a knowledgeable expert on medicines. Furthermore,
they valued the time the pharmacist spent with them,
commenting that this had made them feel special, and
appreciated the opportunity to speak to them privately.
Most accounts suggested that the pharmacist had
reassured patients about their medicines:
Researcher: To what extent then did you personally
find the review useful?
Esther: Well, I think it gave me a bit of confidence that
the pharmacist was caring enough to go though all my
medication to make sure I was happy with it…and
that I knew what I was doing…Patient 61yr. F
Comfort: I think it gives you more confidence, it does
me, gives me more confidence to think I’m doing the
right thing and taking the right medicinePatient 72yr. F
Although pharmacy staff tended to invite patients
with less complicated medicine regimes, there were a
few instances during the MUR where the pharmacist
identified particular concerns about the patient’s
health or medicine. In these cases, rather than inter-
vene directly and on the patient’s behalf, pharmacists
preferred to place the onus on patients to return to
their GP for resolution of these issues. In the follow-
ing example the pharmacist identifies a potential de-
terioration in the patients’ asthma control. Whilst this
event may not have been highlighted unless the
pharmacist had initiated the MUR, the limited remit
and lack of collaboration with the GP led to the
pharmacist closing off discussion and failing to ensure
that the issue was resolved:Jane [Pharmacist]: The Ventolin…
Mia [Patient]: Which ones that? [The patient looks in
her bag and takes out a Ventolin inhaler].Jane: That’s the one, how often do you use that?
Mia: It depends, but I'm using it a lot.Jane: Are you using it eight puffs or more?
Mia: More than that.Jane: You should go to see the asthma nurse or doctor
because the others are not doing their job. If it’s been a
few days you need to see thema.
MUR 32
The follow-up interview with the patient revealed that
the pharmacist’s advice appeared to have been accepted
although it is not known whether the suggestion was
subsequently followed through:
Researcher: … Did you pick up anything that you
didn’t already know?
Mia: …Only that uh I needed to go back, ‘cause the
Ventolin. I just thought it was me getting worse… I
thought I was on the most I could go on, you know and
I’d have to tolerate it. But with her saying that, she
said that they can help you more.Patient 66yr. F
In another case, having discovered non-adherence to a
diuretic tablet, the pharmacist encouraged the patient to
take the medicine as prescribed. A shared decision was
made about informing the GP which was done via the
MUR documentation:
The conversation turns to the patient’s furosemide…
Moya [Patient]: I don’t have ankle swelling so I don’t
take them [furosemide] every day.Rebecca [Pharmacist]: You need to take them every day
as if you don’t then the kidneys have to work more.
Moya: I will mention that to him [the GP], I've got to
see him.Rebecca: I’ll put that on the [MUR] form [Rebecca
explains that the patient should be taking the tablet
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kidneys to work to clear the fluid”].
Rebecca: Is it ok for me to let the GP know?Moya: Yes, I’m seeing him next week.
MUR 9
In the follow-up interview with the patient it was found
that without the MUR, the patient would not have brought
up the matter with the GP. The patient’s awareness that
the pharmacist would be informing her GP through the
MUR form both legitimised and encouraged her to raise
the matter with the GP:
Moya: … You see my frusemide …I thought well I
don’t get any swelling of my ankles so do I need it
every day? So, I get a bit naughty and I don’t take
them every day. And so of course the pharmacist got
on to me and so I’ve got to tell the doctor…whether it
is something I should be taking every day…
Researcher: OK, would you have discussed it with the
doctor if the pharmacist hadn’t mentioned it?Moya: No, no I’d probably wouldn't …I might have
thought about it and thought well better not say
anything else because I might not be doing the right
thing [laughs]… but I will mention it. I’ll have to
because that form’s gone to him [laughter].
Patient 79yr. F
Another important finding that emerged from the data
was how some patients anticipated that the MUR might
affect their relationship with the GP. A few patients
expressed their awareness of a difference in professional
status and hierarchy between pharmacists and GPs and the
possibility their doctor might be annoyed to find the
pharmacist ‘interfering’ with their medicines without this
being clearly sanctioned by the prescriber. As a result, some
felt wary of the pharmacist’s involvement or felt that they
were going behind the doctor’s back, and that MURs had
the potential to cause inter-professional tension or conflict:
Ashley: I don’t think they [GP] like it, outside
interference…being from a novice, a pharmacist or
anybody else…
Patient 67yr. MNicola: I just recently started taking paracetamols…
I did ask the doctor if I could take up to six and shesaid eight. So I just wanted to make sure with the
other tablets…I wouldn’t want my doctor to know that
[laughs]… I didn’t want to upset the doctor by thinking
I was asking her if it was OK to take them … But I
just wanted to check…
Patient 68yr. F
The pharmacist perspective
All the pharmacists interviewed reported enjoying the
activity of undertaking an MUR as this provided greater
personal patient contact and added diversity to their
daily routines. However, they also recognised barriers to
effective implementation of the service. MURs were
being shoehorned alongside existing duties without add-
itional resource. Lack of patient awareness of the avail-
ability and potential value of the service made recruiting
patients difficult. As a result, pragmatic strategies were
employed by pharmacy staff to offer MURs to patients
who met the minimum inclusion criteria and who were
judged likely to respond to an invitation. Patients with
many medicines or those who were perceived to have
more complex conditions such as mental illness were
avoided for fear that the consultation would be too
lengthy. Moreover, organisational pressure on pharmacists
to avoid financial loss by meeting targets for the number
of completed MURs was evident, particularly among those
working in the chain pharmacy:
Jane: Well, it’s not ideal because you’re looking at
figures rather than the actual quality of the service
that you’re giving…
Employee pharmacist, Multiple
Added to these organisational constraints, when phar-
macists were asked about the value of MURs as an
inter-professional collaborative activity, they reported that
patients were not referred from their GPs and they re-
ceived little or no feedback from them about any rec-
ommendations they made regarding medicines which
resulted from the MUR. Consequently, MURs were not
seen to foster inter-professional collaboration: rather,
pharmacists reported the opposite view:
Kate: I don’t think they’re [GP's] keen on us doing it, to
be honest, to be truthful.
Employee pharmacist, Multiple
Discussion
Summary of the main findings
The MUR service has failed to capitalise on a potential
opportunity to foster inter-professional collaboration to
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did not refer patients for MURs and there was no evidence
to suggest that pharmacists and GPs were working in part-
nership to identify the patients who could benefit most
from the service. Pharmacists lacked adequate resources to
implement the service and felt under pressure to reach
targets which caused them to adopt pragmatic strategies of
patient selection, and to routinize the process of the MUR
consultation [38]. Although GPs were notified about
concerns or recommendations resulting from the MUR,
pharmacists received no feedback, and did not engage in
dialogue with GPs about their response to these. Deference
to GPs’ professional status and pharmacists’ perception that
the MUR service was disregarded by GPs further limited
the usefulness of the service. Pharmacists tended to
place the onus on patients to take up issues arising
from the MUR with their GP, which many may have been
reluctant to do, rather than intervene directly. Most pa-
tients reported little improvement in their knowledge of
medicines or alteration to the way they took them. Never-
theless, targeted effectively, MURs have the potential to re-
veal important medicines and health related issues with
substantial impact on healthcare outcomes. Our findings
suggest that there is scope for developing a much more ef-
fective and joined-up service that transcends traditional
boundaries between GPs and pharmacists, reduces the
occurrence of medicine related problems presented to
GPs and supports patients to obtain greater benefit from
their treatments.Comparison with existing literature
Surveys have been used to investigate satisfaction
with the MUR service [26-28,39]. However, there has
been little research investigating ‘live practice’ of the
MUR service and the processes that lead up to and
shape the MUR consultation. This study supports
previous research indicating that MURs have not sig-
nificantly contributed to improving GP-pharmacist re-
lationships or collaboration. Pharmacists’ perceptions
of GP views about MURs, along with continuing def-
erence and reluctance to question GP prescribing de-
cisions, have limited potential collaborative working
opportunities [28-31,40,41]. This is unfortunate as the
literature reports positive results on patient health
outcomes when effective GP-pharmacist collaboration
is promoted [42-45]. Furthermore, this study adds to
existing concerns about how corporate pressure for
pharmacists to meet targets can adversely affect the
recruitment of patients who could benefit most from
the MUR service [30,31,41]. Whereas the GP perspec-
tive of MURs has been reported by others [29,30,32],
further research is needed to pilot and test more inte-
grated collaborative working practice.Implications for future research or clinical practice
Recent reforms to the way pharmacists select patients
have been introduced and include measures that half of
patients invited for MURs are required to be selected
from nationally set target patient groups. These include:
1. patients taking ‘high risk’ medicines (e.g. anticoagulants,
diuretics), 2. recently discharged patients who have had
changes made to their medicines whilst in hospital and 3.
those prescribed medicines for respiratory disease [46].
However, with no signposting from GPs some patients
may remain wary of the purpose of MURs or be reluctant
to fully engage with the service. GPs could, should they
choose, help refer their ‘neediest’ patients for additional
support and seek feedback from pharmacists so they can
better monitor the patient’s condition between visits [47].
GPs could also save themselves time by diverting minor
concerns about prescribed medicines to discussion with the
pharmacist. Research into collaborative working practice is
needed to show how MURs may complement GP practice-
based medication reviews [3]. Research is also needed to
find the most effective way of educating patients on the
extended community pharmacist’s role and MUR so they
feel the activity is approved by all involved in their care and
is genuinely for their benefit. Community pharmacists will
also have to respond and better organise resources required
to deliver MURs and work with practice managers locally
to build mutual rapport and trust if patients are to capitalise
on the potential benefits offered by this service.
Policy makers should consider integrating pharmacy
medicines management services such as the MUR and
the recently introduced New Medicines Service [48] into
the QOF measures to incentivise GP engagement and
position MURs so they complement existing GP medi-
cation reviews. Such measures, as with any collaborative
activity, are dependent upon the willingness of GPs to pro-
vide the service mandate and legitimacy and pharmacists’
readiness to change their practice in order to work in
partnership [17,43-45]. This should encourage shared
values and a common purpose when delivering MURs
so that patients can benefit from a more effective and
appropriately targeted service.
Strengths and limitations of the study
To our knowledge this is the only observational study
that has explored MURs as they occur naturally within a
pharmacy setting. This study used a combination of two
qualitative research methodological approaches to enhance
the credibility of the findings. The triangulation of direct
observation (researcher’s accounts) with accounts provided
by respondents in interviews provided a powerful means of
understanding the complexity of respondents’ views, how
these may shift contextually, the situational pressures which
underlie them and the resulting difference in what people
‘say’ and what they ‘do’. These findings make a significant
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ualise their experience of the MUR and the significance of
the GP-pharmacist relationship.
A well known limitation to fieldwork observations is
the unknown effect of the researcher’s presence on par-
ticipants. The longitudinal nature of the study was
intended to reduce the extent to which participants
modify behaviour as a result of a heightened awareness
of the observer. However, the extent to which this effect
may have influenced our results is unknown. Due to the
cross-sectional design of the study it is difficult to assess
the extent to which advice provided by the pharmacist
was followed by patients over the longer-term. Two
pharmacies were used as study sites and both shared
some characteristics such as levels of affluence in the
patient catchment area and volume of prescriptions
dispensed. Other pharmacy settings, including ones that
may have had more support staff, more diverse patient
populations or different relationships with local GP
surgeries, could have resulted in pharmacists implementing
and performing MURs in a different way and consequently
patients perceiving the service differently. Since conducting
this study, suggested questions to be asked during the
MUR and changes to the format of the MUR have been
made [46]. Future research should seek to explore what
impact these changes have had on patient care and their
perspective of the serviceConclusions
Medicine management services are a key UK health policy
strategy to ensure patients take medicines as prescribed.
These services are increasingly being commissioned
through community pharmacies to support patients with
medicine adherence. Closer collaboration between GPs and
pharmacists could potentially improve patients’ use of
medicines. The current lack of such collaboration con-
stitutes a missed opportunity for pharmacists and GPs
to work together with patients to improve effective
prescribing, optimise patient use of medicines and to
improve health outcomes.Ethical approval
Nottingham NHS Research Ethics Committee.Endnote
a The extracts from the observed MURs that are
presented in this paper are taken from detailed notes
written up after each observation, rather than verbatim
quotes.
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